MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 341086 | Name: Niraxostat
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Niraxostat, also known as Y-700 and Piraxostat, is a novel inhibitor of xanthine oxidase. Y-700 suppresses the development of colon aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine-treated mice. Y-700 is a promising candidate for the treatment of hyperuricemia and other diseases in which XOR may be involved. Y-700 showed high oral bioavailability, which is predominantly eliminated via the liver unlikely to allopurinol.

Chemical Structure

Niraxostat
Niraxostat
CAS#206884-98-2

Theoretical Analysis

MedKoo Cat#: 341086

Name: Niraxostat

CAS#: 206884-98-2

Chemical Formula: C16H17N3O3

Exact Mass: 299.1270

Molecular Weight: 299.33

Elemental Analysis: C, 64.20; H, 5.72; N, 14.04; O, 16.03

Price and Availability

Size Price Availability Quantity
5mg USD 345.00 2 Weeks
25mg USD 1,100.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Niraxostat; Y 700; Y-700; Y700; Piraxostat;
IUPAC/Chemical Name
1-(3-cyano-4-(neopentyloxy)phenyl)-1H-pyrazole-4-carboxylic acid
InChi Key
AETHRPHBGJAIBT-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H17N3O3/c1-16(2,3)10-22-14-5-4-13(6-11(14)7-17)19-9-12(8-18-19)15(20)21/h4-6,8-9H,10H2,1-3H3,(H,20,21)
SMILES Code
O=C(C1=CN(C2=CC=C(OCC(C)(C)C)C(C#N)=C2)N=C1)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Niraxostat is a biochemical.
In vitro activity:
TBD
In vivo activity:
TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 299.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Fukunari A, Okamoto K, Nishino T, Eger BT, Pai EF, Kamezawa M, Yamada I, Kato N. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion. J Pharmacol Exp Ther. 2004 Nov;311(2):519-28. doi: 10.1124/jpet.104.070433. Epub 2004 Jun 9. PMID: 15190124. 2: Hashimoto T, Fukunari A, Yamada I, Yanaka N, Chen D, Kato N. Y-700, a novel inhibitor of xanthine oxidase, suppresses the development of colon aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine-treated mice. Biosci Biotechnol Biochem. 2005 Jan;69(1):209-11. doi: 10.1271/bbb.69.209. PMID: 15665488. 3: Yamada I, Fukunari A, Osajima T, Kamezawa M, Mori H, Iwane J. Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1123-5. doi: 10.1081/NCN-200027384. PMID: 15571214. 4: Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber MJ Jr. Tumor lysis syndrome. Semin Thromb Hemost. 2007 Jun;33(4):397-407. doi: 10.1055/s-2007-976175. PMID: 17525897. 5: Sai Y, Kato Y, Nakamura K, Kato S, Nishimura T, Kubo Y, Tamai I, Yang S, Hu Z, Yamada I, Tsuji A. Carrier-mediated hepatic uptake of a novel nonrenal excretion type uric acid generation inhibitor, Y-700. J Pharm Sci. 2006 Feb;95(2):336-47. doi: 10.1002/jps.20540. PMID: 16369928. 6: Su X, Li W, Sun H, Wang J, Hu S, Yuan F, Zhang D, Wang B. Porous carbon- confined Co x S y nanoparticles derived from ZIF-67 for boosting lithium-ion storage. RSC Adv. 2022 Jan 4;12(2):939-946. doi: 10.1039/d1ra08581f. PMID: 35425149; PMCID: PMC8978921. 7: Bomalaski JS, Clark MA. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep. 2004 Jun;6(3):240-7. doi: 10.1007/s11926-004-0075-3. PMID: 15134605. 8: Zhang TJ, Wu QX, Li SY, Wang L, Sun Q, Zhang Y, Meng FH, Gao H. Synthesis and evaluation of 1-phenyl-1H-1,2,3-triazole-4-carboxylic acid derivatives as xanthine oxidase inhibitors. Bioorg Med Chem Lett. 2017 Aug 15;27(16):3812-3816. doi: 10.1016/j.bmcl.2017.06.059. Epub 2017 Jun 23. PMID: 28693909. 9: Schwendicke F, Stolpe M, Meyer-Lueckel H, Paris S. Detecting and treating occlusal caries lesions: a cost-effectiveness analysis. J Dent Res. 2015 Feb;94(2):272-80. doi: 10.1177/0022034514561260. Epub 2014 Dec 10. PMID: 25503613; PMCID: PMC4438735. 10: Shahraki A, Fukunari A, Stone TW. The mechanism of inhibition by xanthine of adenosine A1-receptor responses in rat hippocampus. Neurosci Lett. 2004 Jul 29;365(3):162-6. doi: 10.1016/j.neulet.2004.04.075. PMID: 15246540.